CROI 2009: Posters/Slides Library

Complications & Coinfections

• Association Between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: the Data Collection on Adverse Avents of Anti-HIV Drugs Study (PDF)
  Colette Smith and the D:A:D Study Group.



• Causes of Death in Patients Treated With ART, 1996 to 2006: Collaborative Analysis of 13 Cohort Studies.
  Gill J, May M, Lewden C, Saag M, Mugavero M, Egger M, Reiss P, Ledergerber B, Mocroft A, Sterne J, and ART Cohort Collaboration



• Contributions of Metabolic Syndrome to Neurocognitive Impairment.
  McCutchan A, Marquie-Beck J, Letendre S, et al, and the CHARTER Group.



• Evaluation of Peripheral Dual Energy X-ray Absorptiometry Bone Densitometry as a Tool for Identification of Low Bone Mineral Density in HIV-Infected Men (PDF)
  Short C-E, Shaw S, Fisher M, Walker-Bone K, Gilleece Y.



• Factors Associated With Mortality in the Study of Fat Redistribution and Metabolic Change in HIV Infection.
  Tien P, Modrich L, Scherzer R, et al, and the FRAM Study.



• High-Density Lipoprotein Particles but Not Low-Density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study.
  Duprez D and INSIGHT/SMART Group.



• High Frequency of Neurocognitive Disorders in Older HIV-Infected Patients Despite a Sustained Virological and Immunological Response on cART: the Sigma Study (PDF)
  Dulioust A, Lerolle N, Dolphin P, et al.



• HIV-associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group Longitudinal Linked Randomized Trials Protocol A5001.
  Evans S, Clifford D, Chen H, et al.



• HIV Infection Is Independently Associated With Detectable Coronary Artery Calcium.
  Hsue P, Deeks S, Schnell A, et al.



• Neuradapt: a Prospective Study Concerning HIV-Related Neurocognitive Impairment
  Vassallo M, Harvey Langton A, Pradier C, et al.



• A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable Background ART in HIV-Infected Subjects: Results from the A5206 Study Team (PDF).
  Tungsiripat M, Kitch D, Glesby M, et al.



• Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? (PDF)
  Falutz J, Rosenthall L.



• Randomized Placebo-Controlled Trial of Prednisone for the TB Immune Reconstitution Inflammatory Syndrome (PDF)
  Meintjes G, Wilkinson R, Morroni C, et al.



• Reasons for Hospitalization That Occurs After HAART Initiation
  Berry SA, Manabe YC, Moore RD.



• Reduced Region-Specific Corpus Callosum Volumes Correlate With Low-Nadir CD4 and Decreased Cognition in HIV-Infected Carriers of the ApoE4 Allele (PDF)
  Kallianpur K, McMurtray A, Valcour V, Shiramizu B, Shikuma C.



• Risk of Myocardial Infarction With Exposure to Specific ARV From the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study (PDF)
  Lundgren J, Reiss P, Worm S, et al, and Aquataine, AHOD, ATHENA, INSIGHT, EuroSIDA, ICONA, Nice, SHCS, St Pierre Cohorts & D:A:D Study Group.



• Serious Fatal and Non-Fatal Non-AIDS-Defining Illnesses in Europe (PDF)
  Mocroft A, Reiss P, Gasiorowski J, et al, and the EuroSIDA Study Group.



• Single-Dose Tenofovir Disoproxil Fumarate With and Without Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants: Pharmacokinetics and Safety (PDF)
  Flynn P, Mirochnick M, Shapiro D, et al, and PACTG/IMPAACT 394 Study Team.



• Untreated HIV Infection is Associated With Impaired Arterial Elasticity (PDF)
  Baker J, Duprez D, Rapkin J, Grimm R, Neaton J, Henry K.



• Updated Surveillance of Cardiovascular Event Rates Among HIV-Infected and HIV-uninfected Californians, 1996 to 2008 (PDF)
  Klein D, Hurley L, Leyden W , et al.

Developing World

• Limits and Realities of ART Scale-up
  Coutinho A.



• High Prevalence of HIV, STI, and Unprotected Anal Intercourse Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in Tamil Nadu, India
  Solomon SS, Srikrishnan A, Sifakis F, et al.



• Incidence Time Trend and Characteristics of Recent Seroconverters in a Rural Community with High HIV Prevalence: South Africa (PDF)
  Barnighausen T, Bangre O, Tanser F, Cooke G, Newell M-L.



• Mortality of HIV-Infected Patients Starting ART: Comparisons With the General Population in Southern Africa (PDF)
  Brinkhof M, Boulle A, Weigel R, et al.

HIV Drug Resistance

• CCR5-Tropic Resistance to Maraviroc is Uncommon Even Among Patients on Functional Maraviroc Monotherapy or With Ongoing Low-level Replication (PDF)
  Jubb B, Lewis M, Simpson P, et al.



• Emerging Patterns of Resistance to Integrase Inhibitors
  Miller M, Danovich R, Witmer M, et al, for the HIV-1 Integrase Inhibitor Devt Teams, Protocol 004 Team, and BENCHMRK-1 and -2 Teams



• Structural Basis for HIV-1 Reverse Transcriptase Drug Resistance to Zidovudine and Tenofovir
  Das K, Tu X, Bandwar R, et al.



• Viral Resistance to the HIV-1 Integrase Inhibitor GS-9160 (PDF)
  Jones G, Yu F, Zeynalzadegan A, et al.

HIV Treatment Strategies

• 96-Week Results From BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART With Triple-Class-Resistant HIV
  Steigbigel R, Cooper D, Eron J, et al, and BENCHMRK-1 and 2 Study Groups.



• Association of HIV-1 Co-receptor Tropism With Immunologic and Virologic Parameters in HIV-1-Infected, Treatment-Naive Subjects in ACTG 384
  Skowron G, J Weidler, G Robbins, et al, and the NIH/NIAID ACTG 384 Protocol Team and Monogram Biosci.



• Characterization of an Outbreak of Acute HCV Infection in HIV-Infected Men in New York City (PDF)
  Fierer D, Fishman S, Uriel A, et al.



• Characterization of Virologic Failures in the Randomized, Controlled, Phase III ARTEMIS Trial in Treatment-Naive Patients: Week-96 Analysis (PDF)
  Dierynck I, De Meyer S, Lathouwers E, et al.



• Comparison of Phenotypic (Trofile) and Genotypic (SensiTrop II) Assays to Determine HIV Tropism in Treatment-Naive Subjects (PDF)
  McCarthy M, Vilchez R, Quiroz J, Strizki J, Liberi J, and Dunkle L.



• Comparison of Trofile and Virotec Tropism Assay in Treatment-Experienced Subjects (PDF)
  Vilchez R, Strizki J, Quiroz J, Dunkle L, and Greaves W.



• Detection of Low-Frequency Mutations Associated With Drug Resistance to Raltegravir Before ART (PDF)
  Liu J, Miller M, Danovich R, et al.



• Differences in Incorporation and Excision of Adenosine Analogues GS-9148 and Tenofovir by HIV-1 Reverse Transcriptase
  Scarth B, White K, Miller M, and Gotte1 M.



• Drug Resistance Monitoring Practices are Strongly Associated With Mortality (PDF)
  Lima V, Eyawo O, Swenson L, Hogg R, Montaner J, Harrigan R.



• Effect of Interleukin-2 on Clinical Outcomes in Patients With a CD4+ Cell Count of 300/mm³: Primary Results of the ESPRIT Study (PDF)
  Guttendorf R, Gulnik S, Eissenstat M, et al.



• Factors Affecting Virologic Response to Darunavir/Ritonavir and Lopinavir/Ritonavir in Treatment-Naive HIV Patients: ARTEMIS at 96 weeks (PDF)
  Nelson M, Yeni P, Sension M, et al.



• GS-9350: A Pharmaco-Enhancer Without Anti-HIV Activity
  Kearney B, Mathias A, Lee M, et al.



• Geographic, Demographic, and Health Status-Related Disparities in Mean Community Viral Load: San Francisco, California (PDF)
  Das-Douglas M, Chu P, Santos D, McFarland W, Colfax G.



• High-resolution Crystallographic Analysis of the Competitive Binding of a Novel Nucleotide Analog GS-9148-Diphosphate to HIV-1 Reverse Transcriptase (PDF)
  Lansdon E, Samuel D, Lagpacan L, et al.



• Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: a Case-control Study Nested Within FHDH ANRS CO4
  Lang S, Mary-Krause M, Cotte L, et al, and the Clinical Epi Group of the French Hosp Database on HIV.



• Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents (PDF)
  Williams P, Staas D, Venkatraman S, et al.



• No Evidence for Decay in the Latent Reservoir in HIV-Infected Patients Receiving Intensive Enfuvirtide-Containing ART
  Gandhi R, Bosch R, Aga E, et al, and ACTG A5173.



• Pharmacokinetics and Safety of Twice-daily Atazanavir (300 mg) and Raltegravir (400 mg) in Healthy Subjects (PDF)
  Zhu1 L, Mahnke1 L, Butterton J, et al.



• Phenotypic Susceptibility to Bevirimat Among HIV-Infected Patient Isolates Without Prior Exposure to Bevirimat (PDF)
  Margot N, Gibbs C, Miller M.



• Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PDF)
  Guttendorf R, Gulnik S, Eissenstat M, et al.



• Simplification With Fixed-Dose Tenofovir/emtricitabine or Abacavir/lamivudine in Adults With Suppressed HIV Replication: the STEAL Study, a Randomized, Open-label, 96-week, Non-inferiority Trial
  Cooper D, Bloch M, Humphries A, et al, for the STEAL Study Investigators.



• Subgroup Analyses From STARTMRK, a Phase III Study of Raltegravir-Based Vs Efavirenz-Based Combination Therapy in Treatment-Naive HIV-Infected Patients (PDF)
  Lennox J, Dejesus E, Lazzarin A, et al.



• Switching From Stable Lopinavir/Ritonavir-Based to Raltegravir-Based Combination ART Resulted in a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-inferior Virologic Efficacy at week 24
  Eron J, Andrade J, Zajdenverg R, et al.



• Transient HAART During PHI Prolongs the Total Time off HAART in Patients Presenting With PHI: Data From the Dutch Primo SHM Cohort
  Steingrover R, Jurriaans S, Grijsen M, de Wolf F, Lange J, Prins J, and the Primo-SHM Study Group.



• Viral Dynamics and Pharmacokinetics in Vivo of Tenofovir Disoproxil Fumarate and Abacavir: Evidence of a Nonadditive Antiviral Effect (PDF)
  Goicoechea M, Jain S, Kemper C, et al, and California Collaborative Treatment Group.



• When Should HIV-1-Infected Persons Initiate ART? Collaborative Analysis of HIV Cohort Studies.
  Sterne J, and the When To Start Consortium.

Pediatric HIV/AIDS

• Discontinuation of ART Among Children With Perinatally Acquired HIV Infection
  Siberry G, Patel K, Burchett S, et al, and the Pediatric HIV/AIDS Cohort Study.



• Double-Dose Lopinavir/Ritonavir Provides Insufficient Lopinavir Exposure in Children Receiving Rifampicin-Based Anti-TB Treatment.
  McIlleron H, Ren Y, Nuttall J, et al.



• Language Impairment in 7- to 16-Year-Old Perinatally HIV-Infected Children
  Rice M, Williams P, Malee K, et al for the Pediatric HIV/AIDS Cohort Study (PHACS).



• Pharmacokinetics and Dose Selection of Etravirine in HIV-Infected Children Between 6 and 17 years, Inclusive (PDF)
  Königs C, Feiterna-Sperling C, EspositoS , et al.

HIV Testing and Prevalence

• A Clinical Study of Antigen/antibody Rapid Testing for Acute HIV Infection
  Pilcher C, Louie B, Keating S, et al.



• Detection of HIV-1 RNA in Seminal Plasma Samples From Treated Patients With Undetectable HIV-1 RNA in Blood Plasma
  Marcelin A-G, Tubiana R, Lambert-Niclot S, et al, and the Pitie-Salpetriere AMP a Risque Viral Study Group.



• Estimated Prevalence of Undiagnosed HIV Infection: US, End of 2006 (PDF)
  Campsmith M, Rhodes P, Hall I.



• False Positive Rate of Rapid Oral Fluid HIV Tests Increases as Kits Near Expiration Date (PDF)
  Facente S, Dowling T, Vittinghoff E, Sykes D, Colfax G.



• HIV Testing and Monitoring in Privately Insured Members Recently Diagnosed With Suspected AIDS-Defining Events (PDF)
  Chen J, Tian H, Dahlin-Lee E, et al.



• Limitations of Rapid HIV Antibody Testing in a Population With High Incidence of HIV Infection
  Stekler J, Swenson P, Coombs R, et al.



• Long-Term Impact of a Behavioral Change Intervention on HIV, STI, Knowledge, Attitudes, and Reported Sexual Behaviors Among Young People in Rural Mwanza, Tanzania: Results of a Community Randomized Trial
  Doyle A, Ross D, Maganja K, Changalucha J, Hayes R, and MEMA kwa Vijana Trial Team.

Women and HIV/AIDS

• Effect of Hormonal Contraception on HIV Disease Progression: a Multi-Country Cohort Analysis (PDF)
  Stringer E, Sinkala M, Gigant M, et al, and the MTCT Plus Initiative.



• Effect of Maternal HAART on Postnatal HIV-1 Transmission After Cessation of Extended Infant Antiretroviral Prophylaxis
  Taha T, Kumwenda J, Cole S, et al.



• Estimated Number of Births to HIV+ Women in the US, 2006 (PDF)
  Whitmore S, Zhang X, Taylor A.



• Metabolic Abnormalities in Behaviorally Infected Young Women: Preliminary Results of Adolescent Medicine Trials Network for HIV/AIDS interventions, ATN 021 (PDF)
  Mulligan K, Monte D, Harris R, et al, and ATN 021 Protocol Team.